SWI Initiates Coverage on CBMG

 SWI Initiates Coverage on
Cellular Biomedicine Group


Presents at the 8th Annual OneMedForum
7th Annual BioTech Showcase in San Francisco
Investing in the Immuno-Oncology Revolution

Wide World of Stocks Broadcast CEO Interview

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. CBMG is the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. CMBG’s cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China. CMBG’s corporate business development strategy has two approaches: partnering our programs at the stage of early to mid-clinical development (i.e.: Knee Osteoarthritis, Cartilage Damage, Asthma), and licensing other applications after seeing them through the proof of concept stage.
Cellular Biomedicine Group brings together the world’s latest technology with industry-leading scientists and professors to research and develop safe treatments for those with serious conditions and diseases. CBMG is proud to have a share in an emerging field that has great potential for a significant positive impact on society. The company’s directors, scientists, doctors and employees share a sense of responsibility that ensures it maintains stringent international safety and quality control standards and focus on the patients and caregivers who will benefit the most from the application of breakthroughs in regenerative medicine.
Company Highlights
  • Robust product pipelines addressing multiple large market opportunities
  • Two products currently in clinical trials
  • Highly experienced executive and scientific team
  • GMP-certified facilities in the PRC designed to international, U.S. FDA standards, and Chinese regulatory bodies’ standards
  • The first cellular medicine company in China accredited with IS0 (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS
Cellular Biomedicine Group was founded in 2009 as a specialty biomedicine company by a team of seasoned Chinese-American executives, scientists and doctors.  CBMG maintains offices in Palo Alto, California, in Hong Kong, and in Shanghai, Beijing and Wuxi, China.  In 2010 it established a research and development facility in Wuxi, China, and in 2012 it established an international-standard protocol-compliant manufacturing facility in Shanghai, China. CMBG’s focus has been to monetize the rapidly growing health care market in China by marketing and commercializing progenitor cell and immune cell therapeutics, related tools and products from our homegrown cell technology, as well as utilizing exclusively in-licensed intellectual properties.

CBMG is focused on developing and marketing safe and effective regenerative and cell-based therapies based on its cellular platforms, to treat serious injury and degenerative diseases including cancers, orthopedic diseases including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases. CMBG has developed proprietary practical knowledge in the use of cell-based therapeutics that it believes could be used to help a great number of people suffering from cancer and serious chronic diseases. CMBG has two therapies undergoing clinical studies in China: stem cell based therapies to treat knee osteoarthritis (“KOA”) and an immune cell therapy to treat liver cancer (“HCC”). CMBG has initiated preclinical studies in Asthma, and Chronic Obstructive Pulmonary Disease (“COPD”) and clinical research studies in cartilage defect stem cell therapy.
In addition to standard protocols, CMBG uses proprietary processes and procedures for manufacturing our cell lines, comprised of:
  • Banking processes that ensure cell preservation and viability;
  • DNA identification for stem cell origin chain of custody; and
  • Bio-safety testing at independently certified laboratories
About SWI
SWI is a leading edge information marketing service with a highly frequented web site and its "Rise Above The Noise" newsletter. The Newsletter informs you about new and promising discoveries. The periodical "Portfolio Performance Report" reports on the performance of the stocks that we have purchased and are holding in the SWI portfolio. The weekly "SWI QuickPicks" Ratings Report keeps you informed about newly initiated stocks and potential upgrades and downgrades in the QuickPicks section on our StockWatchIndex website. We do not necessarily hold positions in any of these stocks. SWI QuickPicks represent the consolidated opinions of carefully selected financial analyst blogs and opinions of Wall Street firms that we respect and frequently sample. You can conveniently follow the live links for each stock on for more detail. Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site
Google +
SWI Investment Criteria
We do not necessarily present stocks for "day-trading-profits", although following our news could create the opportunity to do so. Our recommendations are never solely based on the day's or week's performance, or on an anticipated awareness campaign. They are based on current and past performance, analysis of the current and projected financial position, as well as the expectation that we have for the general performance of the Company going forward. Actual results always depend on the timely implementation of the company's business plan. SWI picks companies at an early stage of their development that it (and other credible analysts) believe have a solid core business model and good potential for success. This service for our subscribers is meant to convey a "quick" reflection of the market mood for certain stocks, which may inspire you to depart on your own research. We disclose in the individual stock and/or analyst reports if any of the companies or third parties may have compensated us for distributing the information about their companies. Do not solely rely on the opinions expressed in this publication, always talk to your personal investment adviser before making an investment decision. Be aware that investing into penny stocks represents a high risk investment and you can potentially loose your entire investment.
Good luck and please pass this newsletter on to a friend
to continue building our community.

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in the publications for its Stock Watch List or on its web sites. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. We have contracted with (MEDL) and some of the other companies we represent as public relations consultants to keep the market and especially our subscribers informed about the company and are being compensated in cash and stock options. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or on its web sites. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice..

Copyright © 2015 StockWatchIndex, LLC, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp